Abstract
Oncolytic HSV-1 has been developed as a novel anticancer agent. According to the properties and functions of HSV-1 encoded proteins, several genes have been targeted for engineering of oncolytic HSV-1. As a result, a variety of strategies have been applied to the engineering of oncolytic HSV-1. Success in cancer therapy for solid tumors requires a maximal oncolytic effect; however, recombinant HSV-1 that has been adapted to meet neurotoxicity requirements for the treatment of brain tumors may be too highly attenuated for effective use in solid tumors outside the brain. Recently, there has been renewed interest in the high potency of naturally oncolytic viruses. In this review, we will overview the engineered oncolytic HSV developed thus far, as well as its mechanism of selectivity and its mode of spreading within tumors. We also discuss the preclinical and clinical studies of HF-10, a non-engineered oncolytic HSV-1 virus, and its potential for use in cancer gene therapy.
Keywords: Gene therapy for cancer, solid tumors outside of the brain, engineered oncolytic virus, non-engineered and naturally occurring HSV1 HF10, PKR signaling pathway, activation of immune system, HSV amplicon system, carrier cell strategy
Current Gene Therapy
Title: Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene Therapy
Volume: 8 Issue: 3
Author(s): Akihiro Nawa, ChenHong Luo, Lumin Zhang, Yoko Ushjima, Daisuke Ishida, Maki Kamakura, Yasushi Fujimoto, Fumi Goshima, Fumitaka Kikkawa and Yukihiro Nishiyama
Affiliation:
Keywords: Gene therapy for cancer, solid tumors outside of the brain, engineered oncolytic virus, non-engineered and naturally occurring HSV1 HF10, PKR signaling pathway, activation of immune system, HSV amplicon system, carrier cell strategy
Abstract: Oncolytic HSV-1 has been developed as a novel anticancer agent. According to the properties and functions of HSV-1 encoded proteins, several genes have been targeted for engineering of oncolytic HSV-1. As a result, a variety of strategies have been applied to the engineering of oncolytic HSV-1. Success in cancer therapy for solid tumors requires a maximal oncolytic effect; however, recombinant HSV-1 that has been adapted to meet neurotoxicity requirements for the treatment of brain tumors may be too highly attenuated for effective use in solid tumors outside the brain. Recently, there has been renewed interest in the high potency of naturally oncolytic viruses. In this review, we will overview the engineered oncolytic HSV developed thus far, as well as its mechanism of selectivity and its mode of spreading within tumors. We also discuss the preclinical and clinical studies of HF-10, a non-engineered oncolytic HSV-1 virus, and its potential for use in cancer gene therapy.
Export Options
About this article
Cite this article as:
Nawa Akihiro, Luo ChenHong, Zhang Lumin, Ushjima Yoko, Ishida Daisuke, Kamakura Maki, Fujimoto Yasushi, Goshima Fumi, Kikkawa Fumitaka and Nishiyama Yukihiro, Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene Therapy, Current Gene Therapy 2008; 8 (3) . https://dx.doi.org/10.2174/156652308784746422
DOI https://dx.doi.org/10.2174/156652308784746422 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Cancer Hygiene Hypothesis: From Theory to Therapeutic Helminths
Current Cancer Therapy Reviews Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment
Current Medicinal Chemistry The Role of CD8+ T Cells in Multiple Sclerosis and its Animal Models
Current Drug Targets - Inflammation & Allergy Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Clinico-Pathologic Function of Cerebral ABC Transporters – Implications for the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer
Current Radiopharmaceuticals A Definitive Pharmacophore Modelling Study on CDK2 ATP Pocket Binders: Tracing the Path of New Virtual High-Throughput Screenings
Current Drug Discovery Technologies Thymidine Phosphorylase Over-Expression in Oral Squamous Carcinoma Tissue as a Potential Target of Capecitabine
Letters in Drug Design & Discovery p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Synthesis and In vitro/In vivo Characterization of Raloxifene Grafted Poly(Styrene Maleic Acid)-Poly(Amide-Ether-Ester-Imide) Micelles for Targeted Delivery of Docetaxel in G Protein-Coupled Estrogen Receptor Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry To Preliminarily Evaluate The Anticancer Activiy of 1,2-di(quinazolin-4- yl)diselane Against MDA-MB-435 Cells in vitro
Letters in Drug Design & Discovery Structural Features of Angiotensin-I Converting Enzyme Catalytic Sites: Conformational Studies in Solution, Homology Models and Comparison with Other Zinc Metallopeptidases
Current Topics in Medicinal Chemistry Labelling and Tracking of Human Mesenchymal Stromal Cells in Preclinical Studies and Large Animal Models of Degenerative Diseases
Current Stem Cell Research & Therapy Biomarkers of Immunity and Inflammation for use in Nutrition Interventions: International Life Sciences Institute European Branch Work on Selection Criteria and Interpretation
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Modeling Approaches in the Discovery of New Drugs for Anti-Cancer Therapy: The Investigation of p53-MDM2 Interaction and its Inhibition by Small Molecules
Current Medicinal Chemistry Having a Promising Efficacy on Type II Diabetes, It’s Definitely a Green Tea Time
Current Medicinal Chemistry Dissecting Virus-Plant Interactions Through Proteomics Approaches
Current Proteomics Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry